Development of HIV Broadly Neutralizing Antibody Susceptibility Assays (R61/R33 Clinical Trial Not Allowed)

Archived

National Institutes of Health

Description

This funding opportunity will support high risk, milestone-driven research for the development of innovative assays designed to enable the measurement of HIV susceptibility to broadly neutralizing antibodies (bNAbs) in clinical laboratories. Proposed studies should target early-stage assay development and demonstrate feasibility and clinical utility, followed by verification and late stage validation of the method. Collaborative, interdisciplinary research with partnerships between academia and industry is strongly encouraged.

Who can apply

  • State governments
  • County governments
  • City or township governments
  • Special district governments
  • Independent school districts
  • Public and State controlled institutions of higher education
  • Native American tribal governments (Federally recognized)
  • Public housing authorities / Indian housing authorities
  • Native American tribal organizations (other than Federally recognized)
  • Nonprofits with 501(c)(3) status (other than higher education)
  • Nonprofits without 501(c)(3) status (other than higher education)
  • Private institutions of higher education
  • For-profit organizations other than small businesses
  • Small businesses
  • Others

Contact

NIH OER Webmaster<br/>OERWebmaster03@od.nih.gov
OERWebmaster03@od.nih.gov

Key dates & funding
  • PostedMar 10, 2022
  • ClosesAug 3, 2022
  • CFDA93.855
Categories

Pro insight

Edit and export this grant’s proposal template, plus deadline reminders, similar-grant suggestions, and funder history — all available with Pro.

Unlock with Pro